secwatch.observer — SEC 8-K summary
======================================

Issuer:     Septerna, Inc. (SEPN)
CIK:        0001984086
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0001193125-25-064729
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Septerna reports FY2024 net loss of $71.8M, discontinues SEP-786 Phase 1 trial
------------------------------------------------------------------------------

- Discontinued SEP-786 Phase 1 trial after two Grade 3 elevated unconjugated bilirubin events, reversible without liver injury.
- Plans to select a next-generation oral PTH1R agonist candidate by end of 2025 to advance toward clinic.
- SEP-631 MRGPRX2 NAM program on track to initiate Phase 1 trial in 2025 for mast cell diseases.
- Cash, equivalents, and marketable securities $420.8M at Dec 31, 2024; runway into early 2028.
- Appointed Gil Labrucherie as CFO in January 2025; net loss $20.7M in Q4 2024, $71.8M for FY2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1984086/000119312525064729/0001193125-25-064729-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1984086/000119312525064729/d906388d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-064729

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer